☰

Ema Yoshioka - Publications

Affiliations: 
BioMedical Sciences Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada 
Tree Info Grants Similar researchers PubMed Report error

4 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Makino Y, Arakawa Y, Yoshioka E, Shofuda T, Minamiguchi S, Kawauchi T, Tanji M, Kanematsu D, Nonaka M, Okita Y, Kodama Y, Mano M, Hirose T, Mineharu Y, Miyamoto S, et al. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. Bmc Cancer. 21: 1025. PMID 34525976 DOI: 10.1186/s12885-021-08733-4  0.393
2020 Chelakkot VS, Liu K, Yoshioka E, Saha S, Xu D, Licursi M, Dorward A, Hirasawa K. MEK reduces cancer-specific PpIX accumulation through the RSK-ABCB1 and HIF-1α-FECH axes. Scientific Reports. 10: 22124. PMID 33335181 DOI: 10.1038/s41598-020-79144-x  0.63
2019 Chelakkot VS, Som J, Yoshioka E, Rice CP, Rutihinda SG, Hirasawa K. Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy. British Journal of Cancer. PMID 31551581 DOI: 10.1038/S41416-019-0586-3  0.586
2018 Yoshioka E, Chelakkot VS, Licursi M, Rutihinda SG, Som J, Derwish L, King JJ, Pongnopparat T, Mearow K, Larijani M, Dorward AM, Hirasawa K. Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway. Theranostics. 8: 2134-2146. PMID 29721068 DOI: 10.7150/Thno.22641  0.588
Show low-probability matches.